Argent BioPharma Ltd - Subiaco, Western Australia-based drug discovery company - Pretax loss narrows to A$17.5 million in the financial year ended June 30, from A$21.1 million a year prior. Revenue from contracts with customers dives to A$891,083 from A$3.4 million. Cost of sales decrease to A$687,386 from A$1.9 million. Notably, Argent Biopharma reports a gain from a fair value movement on financial instruments of A$1.3 million, compared to a cost of A$4.5 million in financial 2023.

Current stock price: 16.15 pence each, closed 13% lower on Friday in London

12-month change: down 23%

Copyright 2024 Alliance News Ltd. All Rights Reserved.